Dyadic International (DYAI) Competitors $1.34 -0.06 (-4.29%) Closing price 04:00 PM EasternExtended Trading$1.30 -0.05 (-3.36%) As of 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DYAI vs. LYEL, TARA, FULC, IVA, IKT, FDMT, IPHA, TNGX, KOD, and PBYIShould you be buying Dyadic International stock or one of its competitors? The main competitors of Dyadic International include Lyell Immunopharma (LYEL), Protara Therapeutics (TARA), Fulcrum Therapeutics (FULC), Inventiva (IVA), Inhibikase Therapeutics (IKT), 4D Molecular Therapeutics (FDMT), Innate Pharma (IPHA), Tango Therapeutics (TNGX), Kodiak Sciences (KOD), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical products" industry. Dyadic International vs. Lyell Immunopharma Protara Therapeutics Fulcrum Therapeutics Inventiva Inhibikase Therapeutics 4D Molecular Therapeutics Innate Pharma Tango Therapeutics Kodiak Sciences Puma Biotechnology Lyell Immunopharma (NASDAQ:LYEL) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends, community ranking and institutional ownership. Do insiders & institutionals believe in LYEL or DYAI? 66.1% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 25.1% of Lyell Immunopharma shares are owned by insiders. Comparatively, 28.8% of Dyadic International shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has preferable earnings and valuation, LYEL or DYAI? Dyadic International has higher revenue and earnings than Lyell Immunopharma. Dyadic International is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLyell Immunopharma$61K2,250.52-$234.63M-$1.31-0.35Dyadic International$3.50M11.54-$6.80M-$0.20-6.70 Does the MarketBeat Community favor LYEL or DYAI? Dyadic International received 147 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 64.40% of users gave Dyadic International an outperform vote while only 46.67% of users gave Lyell Immunopharma an outperform vote. CompanyUnderperformOutperformLyell ImmunopharmaOutperform Votes1446.67% Underperform Votes1653.33% Dyadic InternationalOutperform Votes16164.40% Underperform Votes8935.60% Does the media refer more to LYEL or DYAI? In the previous week, Lyell Immunopharma had 4 more articles in the media than Dyadic International. MarketBeat recorded 7 mentions for Lyell Immunopharma and 3 mentions for Dyadic International. Lyell Immunopharma's average media sentiment score of 1.46 beat Dyadic International's score of 0.31 indicating that Lyell Immunopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lyell Immunopharma 4 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyadic International 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, LYEL or DYAI? Lyell Immunopharma has a beta of -0.41, meaning that its share price is 141% less volatile than the S&P 500. Comparatively, Dyadic International has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Is LYEL or DYAI more profitable? Dyadic International has a net margin of -188.09% compared to Lyell Immunopharma's net margin of -323,792.09%. Lyell Immunopharma's return on equity of -34.64% beat Dyadic International's return on equity.Company Net Margins Return on Equity Return on Assets Lyell Immunopharma-323,792.09% -34.64% -30.02% Dyadic International -188.09%-149.16%-59.81% Do analysts recommend LYEL or DYAI? Lyell Immunopharma presently has a consensus price target of $1.00, suggesting a potential upside of 115.05%. Dyadic International has a consensus price target of $6.00, suggesting a potential upside of 347.76%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts plainly believe Dyadic International is more favorable than Lyell Immunopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyell Immunopharma 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Dyadic International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryDyadic International beats Lyell Immunopharma on 11 of the 18 factors compared between the two stocks. Remove Ads Get Dyadic International News Delivered to You Automatically Sign up to receive the latest news and ratings for DYAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DYAI vs. The Competition Export to ExcelMetricDyadic InternationalBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.17M$2.96B$5.58B$7.57BDividend YieldN/A1.53%5.35%4.04%P/E Ratio-5.8030.5822.9818.19Price / Sales11.49388.15362.8486.44Price / CashN/A168.6838.1634.64Price / Book6.683.636.534.03Net Income-$6.80M-$72.06M$3.21B$247.18M7 Day Performance-1.11%-9.84%-5.84%-5.61%1 Month Performance-4.64%-16.02%-0.12%-6.72%1 Year Performance-25.83%-30.11%6.42%-3.53% Dyadic International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DYAIDyadic International2.2708 of 5 stars$1.34-4.3%$6.00+347.8%-20.0%$40.32M$3.50M-5.837Gap DownLYELLyell Immunopharma3.6355 of 5 stars$0.54-0.6%$1.00+85.9%-75.6%$158.83M$61,000.00-0.68270Positive NewsGap DownTARAProtara Therapeutics2.4056 of 5 stars$4.26-7.0%$22.50+428.2%+4.4%$156.63MN/A-1.5130FULCFulcrum Therapeutics1.1957 of 5 stars$2.88-4.3%$8.63+199.5%-68.8%$155.46M$80M-9.29100Gap DownIVAInventiva1.9726 of 5 stars$2.91-0.2%$12.60+333.7%-14.6%$152.45M$15.62M0.00100News CoverageIKTInhibikase Therapeutics1.4171 of 5 stars$2.19-4.4%$6.50+196.8%+1.4%$151.90M$260,000.00-0.826Gap DownFDMT4D Molecular Therapeutics2.1815 of 5 stars$3.23-11.0%$30.63+848.1%-88.3%$149.56M$37,000.00-1.13120IPHAInnate Pharma2.7227 of 5 stars$1.78-10.1%$11.50+546.1%-33.2%$149.22M$24.85M0.00220Gap UpTNGXTango Therapeutics2.0042 of 5 stars$1.37-6.8%$12.33+800.2%-81.9%$148.11M$42.07M-1.1690Short Interest ↑Positive NewsGap DownKODKodiak Sciences3.9349 of 5 stars$2.81-3.4%$8.00+184.7%-38.3%$147.87MN/A-0.7790Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap UpHigh Trading VolumePBYIPuma Biotechnology4.1057 of 5 stars$2.96-5.7%$7.00+136.5%-43.0%$146.85M$230.47M6.17200News CoverageGap Down Remove Ads Related Companies and Tools Related Companies Lyell Immunopharma Alternatives Protara Therapeutics Alternatives Fulcrum Therapeutics Alternatives Inventiva Alternatives Inhibikase Therapeutics Alternatives 4D Molecular Therapeutics Alternatives Innate Pharma Alternatives Tango Therapeutics Alternatives Kodiak Sciences Alternatives Puma Biotechnology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DYAI) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredIt’s Time to Buy Elon’s “ChatGPT Killer”Elon Musk’s new AI model is blowing everyone’s mind. It has been called “a game-changer in AI innovation”.....Brownstone Research | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredWhy Elon Musk Is Investigating Fort KnoxWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyadic International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyadic International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DYAI Stock Free DYAI Stock Alerts